📣 VC round data is live. Check it out!
- Public Comps
- Bioretec
Bioretec Valuation Multiples
Discover revenue and EBITDA valuation multiples for Bioretec and similar public comparables like aap Implantate, Acarix, BrainCool, Carclo and more.
Bioretec Overview
About Bioretec
Bioretec Ltd is a medical device company focusing on the development of safe, and reliable bioabsorbable and bioresorbable implants for pediatric and adult orthopedics. The company's products are used world wide and continue to further develop materials and products for high-load-bearing clinical applications. Some of its brands include RemeOs, Activa IM-N, ActivaPi, and ActivaScrew.
Founded
2003
HQ

Employees
47
Website
Financials (LTM)
EV
$29M
Valuation Multiples
Start free trialBioretec Financials
Bioretec reported last 12-month revenue of $5M and negative EBITDA of ($9M).
In the same LTM period, Bioretec generated ($10M) in gross profit, ($9M) in EBITDA losses, and had net loss of ($10M).
Revenue (LTM)
Bioretec P&L
In the most recent fiscal year, Bioretec reported revenue of $4M and EBITDA of ($10M).
Bioretec is unprofitable as of last fiscal year, with gross margin of 65%, EBITDA margin of (233%), and net margin of (264%).
Financial data powered by Morningstar, Inc.
Bioretec Stock Performance
Bioretec has current market cap of $33M, and enterprise value of $29M.
Market Cap Evolution
Bioretec's stock price is $0.02.
Bioretec share price decreased by 5.5% in the last 30 days, and by 98.8% in the last year.
Bioretec has an EPS (earnings per share) of $-0.01.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $29M | $33M | -2.8% | -5.5% | -65.1% | -98.8% | $-0.01 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialBioretec Valuation Multiples
Bioretec trades at 5.8x EV/Revenue multiple, and (3.2x) EV/EBITDA.
EV / Revenue (LTM)
Bioretec Financial Valuation Multiples
As of June 4, 2026, Bioretec has market cap of $33M and EV of $29M.
Bioretec has a P/E ratio of (3.2x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Bioretec Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Bioretec Margins & Growth Rates
Bioretec grew revenue by 47% but EBITDA decreased by 20% in the last fiscal year.
In the most recent fiscal year, Bioretec reported gross margin of 65%, EBITDA margin of (233%), and net margin of (264%).
Bioretec Margins
Bioretec Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Bioretec Operational KPIs
Bioretec's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.3M for the same period.
Bioretec's Rule of 40 is (78%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Bioretec's Rule of X is (3%) (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Bioretec Competitors
Bioretec competitors include aap Implantate, Acarix, BrainCool, Carclo, Vivos, Ortoma, NeuroOne Medical, CytoSorbents, Implanet and Diagnostic Medical Systems.
Most Bioretec public comparables operate across Medical Devices, HealthTech and DeepTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 2.3x | - | (42.9x) | - | |||
| 35.3x | 21.8x | (6.1x) | (7.2x) | |||
| 6.6x | 6.4x | (7.9x) | (9.2x) | |||
| 0.4x | 0.4x | 3.0x | 2.7x | |||
| - | - | - | - | |||
| 4.5x | 4.4x | (69.8x) | (23.1x) | |||
| 3.1x | 2.7x | (9.4x) | - | |||
| 1.5x | 1.4x | (12.5x) | - | |||
This data is available for Pro users. Sign up to see all Bioretec competitors and their valuation data. Start Free Trial | ||||||
Bioretec VC Funding History
Before going public, Bioretec raised $9M in total equity funding, across 1 round.
Bioretec Funding Rounds
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Bioretec
| When was Bioretec founded? | Bioretec was founded in 2003. |
| Where is Bioretec headquartered? | Bioretec is headquartered in Finland. |
| How many employees does Bioretec have? | As of today, Bioretec has over 47 employees. |
| Is Bioretec publicly listed? | Yes, Bioretec is a public company listed on Nasdaq Helsinki. |
| What is the stock symbol of Bioretec? | Bioretec trades under BRETEC ticker. |
| When did Bioretec go public? | Bioretec went public in 2022. |
| Who are competitors of Bioretec? | Bioretec main competitors include aap Implantate, Acarix, BrainCool, Carclo, Vivos, Ortoma, NeuroOne Medical, CytoSorbents, Implanet, Diagnostic Medical Systems. |
| What is the current market cap of Bioretec? | Bioretec's current market cap is $33M. |
| What is the current revenue of Bioretec? | Bioretec's last 12 months revenue is $5M. |
| What is the current revenue growth of Bioretec? | Bioretec revenue growth (NTM/LTM) is 51%. |
| What is the current EV/Revenue multiple of Bioretec? | Current revenue multiple of Bioretec is 5.8x. |
| Is Bioretec profitable? | No, Bioretec is not profitable. |
| What is the current EBITDA of Bioretec? | Bioretec has negative EBITDA and is not profitable. |
| What is Bioretec's EBITDA margin? | Bioretec's last 12 months EBITDA margin is (182%). |
| What is the current EV/EBITDA multiple of Bioretec? | Current EBITDA multiple of Bioretec is (3.2x). |
| What is the current FCF of Bioretec? | Bioretec's last 12 months FCF is ($8M). |
| What is Bioretec's FCF margin? | Bioretec's last 12 months FCF margin is (157%). |
| What is the current EV/FCF multiple of Bioretec? | Current FCF multiple of Bioretec is (3.7x). |
| How many companies Bioretec has acquired to date? | Bioretec hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Bioretec has invested to date? | Bioretec hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Bioretec
Lists including Bioretec
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.